Navigation Links
Cancer immunotherapy shows long-term promise in lung cancer
Date:4/24/2008

mes poorly tolerated by patients recovering from thoracic surgery. In addition, not all patients are fit to receive chemotherapy. This is why the signal from this phase II randomized study is important: the reduction in risk of postoperative cancer relapse is similar to the one obtained with postoperative chemotherapy, while the side-effects of this new strategy are minimal compared to chemotherapy."

Most patients only experience mild reactions at the injection site and fever within 24 hours of the injection, he explained. "Therefore, it is suitable for long-term maintenance treatment and for most patients, including older patients or patients in weak physical condition after surgery, allowing them to live a normal life whilst on cancer treatment." A large Phase III trial of the therapy, named MAGRIT, is now underway.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers reveal structure of protein that repairs damage to cancer cells
2. Pregnancy is possible after cancer treatment
3. Effective cancer immune therapy through order in the blood vessels
4. Fox Chase researchers discover a method for clamping down on a cancer-promoting enzyme
5. Breast cancers behave differently before and after the age of 70
6. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
7. Ovarian cancer stem cells identified, characterized
8. Inherited cancer mutation is widespread in America
9. New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
10. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
11. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2
... The Translational Genomics Research Institute (TGen) provides Arizona with ... to the results of an independent analysis released today. ... TGen-led research, a study by the research firm Tripp ... to $321.3 million by 2025. "As we make ...
... September 28, 2009 -- Soybeans contain high ... have antioxidant properties. These molecules can be used ... specific health-beneficial properties and can be used in ... in four forms (α, β, γ, and δ) ...
... biology continue to develop as two of the most ... that the public is almost completely unaware of the ... American adults conducted by Peter D. Hart Research Associates ... 90 percent of Americans think the public should be ...
Cached Biology News:TGen provides Arizona with $77 million in annual economic impact 2TGen provides Arizona with $77 million in annual economic impact 3Eat soybeans to prevent diseases 2Nanotechnology and synthetic biology: What does the American public think? 2
(Date:10/20/2014)... Mapp Biopharmaceutical,s valiant effort to produce ... fight the Ebola outbreak will make the public ... of pharmaceuticals can be, according to Kalorama Information.  ... some may be taken aback by the three-month ... knowledge are well aware of the complex issues ...
(Date:10/20/2014)... Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... brings Q3 orders to $5.8 million and provides a good start ... North America and one in the ... new projects at record levels," said Peter Bruijns , President ... the end of Q3 than they have been for any complete ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/20/2014)... 2014 Local veterinary surgeon, Dr. Tim ... study of donor stem cells for dogs with osteoarthritis. ... and has performed clinical stem cell therapy for 7 ... determine if a single injection of donor stem cells ... reduce pain and inflammation in the treated joints. ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Oct. 30 Cephalon, Inc. (Nasdaq:,CEPH) today announced that ... held on,November 5, 2008, will be webcast live on ... ., Cephalon,s senior management will review the company,s ... will be delivered on Wednesday, November 5, 2008 beginning ...
... - Cytochroma today announced the,appointment of Ulrik Spork to ... on the Company,s Board and replaces Dr. Soren Schifter,who ... remains unchanged at,six members., "We are very pleased ... to drawing on his expertise and experiences as we ...
... Discuss Continued Expansion of DXL(TM) Patent Protection at ... 7th Annual BIO ... InNexus,Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;, http://www.ixsbio.com ... antibodies based on its Dynamic Cross Linking,(DXL(TM)) technology, announced today ...
Cached Biology Technology:Cephalon, Inc. to Webcast Analyst Day 2Cephalon, Inc. to Webcast Analyst Day 3InNexus Biotechnology Receives Patent Grants in Europe 2
... is an integrated digital microscope and camera ... equipment setup, optical adjustment or software installation. ... technology, COOLSCOPE combines simplicity and advanced technology ... offers simultaneous viewing of a macro image ...
... microscope is described by end-users to be ... the fundamentals of light microscopy and electronic ... footprint, it does not require much space ... busy lab environment. The DM-BA300 combines Motic's ...
... The TUNEL-based assay kit provides complete ... cells for convenient detection of DNA ... sections. The incorporation of BrdU in ... biotinylated or digoxigenylated methods. Results can ...
... ergonomic microscopes are now available in digital ... DM-BA200 comes packed with Motic's patented Colour ... plug and play digital image capture head. ... a reversed quadruple nosepiece, deliver high quality ...
Biology Products: